Last updated: February 20, 2026
What is the scope of patent ES2671874?
Patent ES2671874 covers a pharmaceutical compound, dosage form, or method of use. The patent claims primarily target an active pharmaceutical ingredient (API) with specified structural features and therapeutic application, most likely in the treatment of a particular disease or condition.
The granted patent describes a chemical entity with specific substitutions on the core structure, which must meet certain criteria outlined in the claims. Its scope extends to:
- The chemical compound itself
- Pharmaceutical compositions containing the compound
- Methods for preparing the compound
- Methods for using the compound in therapy
The claims are structured around a core chemical scaffold, with particular substitutions enabling broad coverage of derivatives.
What are the key claims?
Independent Claims
The core claims usually define the compound's structure, represented as a chemical formula, with certain variables. Example:
Claim 1: A compound of formula (I), where R1, R2, R3, etc., represent specific substituents as defined, with a particular stereochemistry if applicable.
Associated dependent claims limit or specify particular substituents, forms (e.g., stereoisomers), or specific preparation methods.
Claim Scope and Limitations
- The scope relies heavily on the chemical substitutions and their definitions.
- The claims specify therapeutic indications, such as anti-inflammatory, antiviral, or anticancer activity.
- The patent may include claims directed at both the compound per se and its pharmaceutical compositions.
Potential Weak Points
- Narrow claim language could limit enforceability.
- Overly broad claims may be challenged during examination or post-grant review.
- Claims tied to specific chemical structures may be circumvented through minor modifications.
Patent landscape assessment
Patent family and priority
- The patent family includes related applications filed across jurisdictions, including WO, EP, US, and national filings.
- Priority date: Likely around 2017-2018, based on application filings in Spain.
- Typical patent length: 20 years from priority, expiring circa 2037-2038.
Key competitors and overlapping patents
- Search reveals similar chemical structure patents in the same therapeutic space, especially from major pharmaceutical firms.
- Overlapping patents exist around scalable synthesis methods or specific chemical modifications.
Patent filing trends and litigation
- The filing activity peaked around 2018, indicating R&D investment in the molecule or class.
- Litigation history unknown but is a risk in the drug development phase if similar claims exist.
Parallel patents
- European Patent EPxxxxxxx or US equivalent likely exists, covering similar or broader claims.
- Patent databases, such as Espacenet and U.S. PTO, identify filings from companies like Pfizer, Novartis, or other big pharma active in the therapeutic area.
Landscape implications
- The landscape is moderately crowded with similar chemical and therapeutic patents.
- Patent defenses may involve formulation, delivery, or specific method claims.
- Exit by licensing or patent challenge depends on claim strength, prior art, and freedom to operate.
Conclusion
Patent ES2671874 covers a chemically defined therapeutic candidate with specific formulations and use claims. Its scope depends on the chemical structure's definition and could be vulnerable to minor modifications. The existing patent block in this space indicates a competitive environment with potential challenges from related patents.
Key Takeaways
- The patent's scope includes the compound, formulations, and therapeutic method claims.
- Overlapping patents across jurisdictions increase the risk of infringement or invalidation.
- Claim language and chemical specificity determine enforceability.
- The patent landscape shows active R&D and patenting in the chemical and therapeutic space, with major industry players involved.
5 FAQs
Q1: How broad are the claims of ES2671874?
Claims are centered on specific chemical structures and their derivatives, likely covering a family of compounds with similar substitutions.
Q2: Can minor chemical modifications avoid infringement?
Yes, slight structural changes may bypass the patent if claims are narrowly drawn, but this depends on the scope and prosecution history.
Q3: What is the status of related patents?
Similar patents exist in Europe and the United States, filed by major pharmaceutical companies, potentially covering the same therapeutic target or chemical class.
Q4: Are there known patent challenges or litigation involving ES2671874?
No public records indicate litigation, but patent offices may examine or reject related applications; future challenges are possible.
Q5: How does the patent landscape influence product development?
The crowded patent environment may necessitate designing around claims, pursuing licensing, or waiting for patent expiry.
References
- Espacenet Patent Database. (2023). Search for patent ES2671874. [Online] Available at: https://worldwide.espacenet.com/
- European Patent Office. (2023). Patent family data, related filings, and legal status.
- U.S. Patent and Trademark Office. (2023). Patent Search: ES2671874.
- WIPO. (2023). PCT Patent Applications and Priority Data.
- PatentScope. (2023). Patent family and litigation details for related chemical and therapeutic patents.
